Webinar content

The webinar will include discussion of the latest European biotech patent case law developments including:

• T 0295/22: new mode of administration is capable of establishing novelty for further medical use claim.
• T 0816/22: post-published negative Phase III trial data used to raise doubts as to sufficiency.
• T 0314/20: interpreting G 2/21.

Registration

The webinar will run at 9am, noon and 5pm GMT (UK time) on Tuesday 25 February 2025. To register for your preferred webinar time (and select local time options), please select the appropriate link below:

• Register for the 9am (GMT) webinar
• Register for the 12pm (GMT) webinar
• Register for the 5pm (GMT) webinar

Once your registration has been approved, please be sure to check system requirements to avoid any connection issues.

Speakers

Partner Simon O'Brien is an experienced Chartered and European patent attorney and his expertise encompasses in particular both biological and chemical subject matter, including the fields of molecular biology, biotechnology, biochemistry, plant physiology, diagnostics, pharmaceuticals, and polymer chemistry. Simon represents a number of clients ranging from academic institutions to multinational corporations. Simon advises on all aspects of patent law including patent drafting and prosecution, opposition and appeal proceedings. In particular, he handles the worldwide vaccine patent portfolio for a major pharmaceutical company. He has additionally advised clients completing IP due diligence for stock market flotations. IAM Patent 1000 comments that “O’Brien has the technical expertise and experience to handle even the most delicate and vital matters in a tight timeframe”.

Matthew Caines joined D Young & Co in 2012 and was promoted to partner in 2022. He works on a wide range of biotechnological and chemical subject matter. His practice includes the drafting and prosecution of applications, opposition and appeal proceedings, and freedom to operate opinion work. Matthew has worked for a range of clients, from academic institutes and start-ups to multinational companies. Matthew's doctorate research at the University of Oxford investigated the mechanisms involved in the natural biosynthetic pathway of a clinically important antibiotic. Matthew subsequently undertook postdoctoral research at the University of British Columbia, where his work focused on the structures and mechanisms of enzymes linked to bacterial and viral pathogenesis. His research then took him to the MRC Laboratory of Molecular Biology in Cambridge, where he studied the immune response to HIV and influenza virus infections. Matthew has published nine papers in peer-reviewed journals including Nature Structural & Molecular Biology, Angewandte Chemie and Nature Chemical Biology. Legal 500 2023 describes Matthew as a “top-level patent attorney, having exhaustive knowledge in life sciences technology and considerable experience”.